Celgene

Celgene Corporation was an American multinational biopharmaceutical company based in Summit, New Jersey, focused on developing therapies for cancer, inflammatory and autoimmune diseases, and hematologic disorders. The company pursued an acquisitions-led strategy to expand its product portfolio and pipeline, building a broad suite of oncology and immunology medicines.

Its approved medicines included Revlimid (lenalidomide), a cornerstone therapy for multiple myeloma and various hematologic conditions; Pomalyst (pomalidomide) for multiple myeloma; Vidaza (azacitidine) for myelodysplastic syndromes; Abraxane (nab-paclitaxel) for solid tumors; and Otezla (apremilast) for plaque psoriasis and psoriatic arthritis. Through the 2010 acquisition of Abraxis BioScience, Celgene added Abraxane to its lineup, and the 2009 acquisition of Pharmion expanded its presence in hematologic cancers with Vidaza. In 2015 Celgene acquired Receptos, adding the experimental therapy ozanimod to its pipeline (later marketed by Bristol Myers Squibb as Zeposia).

Celgene's development strategy emphasized oncology and inflammatory diseases, with a pipeline targeting hematologic malignancies, solid tumors, and autoimmune disorders. The company also engaged in collaborations and licensing arrangements to broaden its global reach and accelerate development.

In 2019, Bristol Myers Squibb announced a plan to acquire Celgene for about $74 billion. The transaction closed in November 2019, and Celgene became part of Bristol Myers Squibb. The merger integrated Celgene’s products and pipeline, including Revlimid and the ozanimod program, into BMS's portfolio and research efforts, shaping the combined company's oncology and immunology strategy.